Moreover, BC is a highly heterogeneous disease characterized by different subtypes, such as estrogen receptor (ER+), progesterone receptor (PR+), human epidermal growth factor 2 (HER2+), and triple-negative, that can respond differently to treatments [149]. This evidence concerns the gene PGR and breast cancer.